Table I.

Summary of Model Parameters Used to Simulate the Longitudinal Course of Parkinson’s Disease

Group	Parameter	Mean	Variability (%)
Placebo	Rate of progression (slope)	0.16	50
	Symptomatic effect	0.8	50
	Rate constant for time to attain maximum symptomatic effect	0.693	50
	Baseline UPDRS	25	50
Drug	Rate of progression (slope)	0.16	50
	Symptomatic effect	2	50
	Rate constant for time to attain maximum symptomatic effect	0.693	50
	Baseline UPDRS	25	50

Units for rate of progression (slope)—per week; symptomatic effect—UPDRS; rate constant for time to attain maximum symptomatic effect (ke0)—per week

UPDRS Unified Parkinson’s Disease Rating Scale